Target intelligence / Profile preview

Intestinal microbiota (colonic)

Molecular classification
Other
01

Overview

The intestinal microbiota (colonic) refers to the dense, metabolically active community of microorganisms (primarily bacteria, but also archaea, fungi, viruses) inhabiting the colon and influenced by the local environment, including pH, transit time, nutrient availability, and host immune factors. This ecosystem is critical for fermentation of undigested carbohydrates, production of short-chain fatty acids, immune system maturation, protection against pathogens, and maintenance of colonic health. The colonic environment, characterized by a stable, anaerobic, and nutrient-rich setting, shapes microbial composition, diversity, and their metabolism, which in turn have profound effects on host physiology and disease risk. The entity is not a classical molecular target but rather a complex ecological system, and is thus unsuitable as a "target" in the conventional pharmacological sense.

Other names
Gut microbiotacolonic microbiotagut floragut microbiomeintestinal flora
02

Mechanism of action

Alteration of microbial community structure and metabolic activity (by antibiotics, prebiotics, probiotics, FMT); Modulation of immune responses via microbial metabolites

03

Biological functions

Metabolism of dietary components (e.g., fermentation of dietary fibers to short-chain fatty acids)Colonization resistance to pathogensImmune system modulation and developmentMaintenance of intestinal epithelium integrityProduction and biotransformation of vitamins, bile acids, and other metabolitesRegulation of gastrointestinal motility
04

Disease associations

Inflammatory diseases (e.g., inflammatory bowel disease, irritable bowel syndrome)Metabolic diseases (e.g., obesity, type 2 diabetes)Colorectal cancerInfection (including effects of pathogen overgrowth)Other (role in neurological, autoimmune, and cardiovascular diseases)
05

Safety considerations

Dysbiosis linked to disease states and increased infection riskAntibiotic-associated adverse effects (e.g., Clostridioides difficile overgrowth)Transmission of pathogens via FMT
06

Interacting drugs

Antibiotics (alter microbiota composition)

3 more in the full profile.

07

Biomarkers

Fecal microbial species counts and ratios (e.g., Bacteroides/Firmicutes ratio)Levels of short-chain fatty acids in stoolDiversity indices of microbiotaSpecific metabolites such as trimethylamine N-oxide (TMAO), indole derivatives

Beyond the preview

Go deeper on Intestinal microbiota (colonic).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal microbiota (colonic).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call